Methods for enhancing the bio availability and exposure of a voltage-gated potassium channel opener
US11135214B2 · kind B2 · utility
2Cited by
4References
26Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | May 13, 2019 |
| Grant date | Oct 5, 2021 |
| Priority date | — |
| Expiry date | May 14, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
In certain embodiments, the present disclosure is directed to methods and uses for treating seizure disorders in a human, wherein the methods and uses comprise orally administering a therapeutically effective amount of the voltage-gated potassium channel allosteric modulator, N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A), to the human in need thereof, for example, under fed conditions. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.